Your session is about to expire
← Back to Search
Non-fluoride vs Fluoride Toothpaste for Tooth Decay
Study Summary
This trial will compare the safety and effectiveness of a non-fluoride toothpaste to a fluoride toothpaste in children aged 10-14.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have severe tooth decay in five or more of my permanent teeth.I have moderate to severe gum disease.I am on long-term antibiotics.My child has a confirmed diagnosis of cognitive or motor impairment.I have a severe misalignment of my teeth.I am taking medication that can cause dry mouth or has high sugar.You have had allergic reactions or negative responses to arginine, oral care products, or their ingredients in the past.My second permanent molars have started to come in.I have a dental device or braces on more than four of my teeth.I am committed to following the trial's treatment plan and attending all appointments.I am between 10 and 14 years old.I have two or more active tooth cavities and a history of tooth decay.
- Group 1: 0.24% Sodium Fluoride Dentifrice
- Group 2: 1.5% Arginine Dentifrice
- Group 3: 4.0% Arginine Dentifrice
- Group 4: 8.0% Arginine Dentifrice
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is 1.5% Arginine Dentifrice a safe product for human use?
"Because this is a Phase 2 trial, and thus there is only some data supporting safety but not efficacy, we have estimated the 1.5% Arginine Dentifrice to be a 2 on our safety scale."
Does this experiment blaze any new territory?
"1.5% Arginine Dentifrice is being studied in 20 clinical trials in 27 cities and 12 countries. Baxter Healthcare Corporation first ran a trial for 1.5% Arginine Dentifrice in 2007, which completed Phase 4 drug approval in 2007 with 4640 patients. Since then, 134 trials have been completed."
Will this trial be testing minors?
"In order to participate in this research, potential candidates must be aged 10-14. Out of the 67 ongoing studies, this is one of 40 that specifically looks at this age range."
In how many different locations are subjects being recruited for this hospital-based research?
"There are 11 total sites for this study, 8 of which are enrolling patients. These 8 locations are Indiana University School of Dentistry in Indianapolis, Loma Linda University School of Dentistry in Loma Linda, and UT Health San Antonio School of Dentistry in San Antonio, among others."
What are the most up-to-date findings on the effects of 1.5% Arginine Dentifrice?
"Over the course of 134 completed studies since 2007, 1.5% Arginine Dentifrice has been investigated. There are 20 ongoing trials recruiting patients, a majority of which are based in Indianapolis, Indiana."
What does 1.5% Arginine Dentifrice help to treat?
"Arginine Dentifrice, at a concentration of 1.5%, is often used to treat pituitary dwarfism. However, it has also been clinically shown to be effective against other conditions such as enzymes, pituitary stimulant, and enamel caries."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger